logo

tagline

Speakers

Chairs

Speakers
Prof. Michael P. Manns, Hannover Medical School
Speakers
Prof. Michael P. Manns, Hannover Medical School
_chair

Michael P. Manns is Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), Hannover, Germany since 1991. He graduated in medicine from the University of Vienna in Austria and the University of Mainz in Germany before completing postgraduate training at the Free University of Berlin, Germany, and the University of Mainz, where he became Professor of Medicine in 1986. Subsequently, Professor Manns was a Research Associate at the Scripps Research Institute in La Jolla, California, USA from 1987 to 1988. Professor Manns has a long-term research interest in liver diseases with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular carcinoma, liver transplantation, regenerative medicine, and cell therapy.

Professor Manns is founder and Chairman of Hep-Net, a national network of competence on viral hepatitis, and the German Liver Foundation. He has been President of the German Society of Gastroenterology (DGVS), the German Association for the Study of the Liver (GASL) and the German Society of Internal Medicine (DGIM), and is currently President Elect of United European Gastroenterology (UEG). Professor Manns has received numerous awards including the International Hans Popper Award and the European Association for the Study of the Liver (EASL) Recognition Award in 2007. He organized numerous national and international conferences including the Global Viral Hepatitis Summit on occasion of the 15th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) in Berlin, Germany, in June 2015. Since 2015 he is member of the Scientific Panel for Health (SPH) of the European Commission in Brussels. He has published more than 1000 articles in international peer-reviewed journals such as the New England Journal of Medicine, The Lancet, Nature, Nature Medicine, Cell, Gastroenterology, and Hepatology among others. He has an H-Index of 119. According to Thomson Reuters he ranks among the top 1 % of most cited researchers in clinical medicine.

Speakers
Prof. Angelos Hatzakis, University of Athens
Speakers
Prof. Angelos Hatzakis, University of Athens
_chair

Angelos Hatzakis, MD, PhD, MSc, is Professor of Epidemiology & Preventive Medicine and Director of the Department of Hygiene, Epidemiology & Medical Statistics at Athens University Medical School. He is also Head of the National Retrovirus Reference Center. He trained in Internal Medicine (“Hippokratio” General Hospital of Athens) and Epidemiology (Harvard School of Public Health). He has served in many Executive Committees including the presidency of the Hellenic CDC. Professor Hatzakis is Co-Chair and founder of the Hepatitis B and C Public Policy Association. His research interests cover epidemiology, virology and prevention of viral diseases and oncogenic viruses. He is the author or co-author of more than 200 scientific papers published in journals like Lancet, JAMA, Plos Medicine, British Medical Journal, Annals of Internal Medicine, Proceedings of the National Academy of Science/PNAS, AIDS, Journal of AIDS, Journal of Infectious Diseases, Hepatology, Gastroenterology, Antiviral Therapy, Blood, Cancer Research, Pediatrics etc.

Speakers
Prof. Pierre van Damme, University of Antwerp & VHPB
Speakers
Prof. Pierre van Damme, University of Antwerp & VHPB
_chair

Professor Van Damme is full professor at the University of Antwerp, Faculty of Medicine and Health Sciences. He chairs the Vaccine & Infectious Disease Institute (VAXINFECTIO, University of Antwerp, a consortium of three research units within the university: the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and the Centre for the Evaluation of Vaccination (CEV) which was founded by Pierre Van Damme in 1994. It is recognized as ‘Centre of Excellence’ of the University of Antwerp and functions as WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases.

Professor Van Damme gained his MD from the University of Antwerp in 1984. He was recruited in 1985 to work on the epidemiology and prevention of hepatitis B in institutions for the mentally impaired. He subsequently obtained post-graduate degrees in health and economics, the evaluation of human corporal damage, and a master degree in occupational health. He obtained his PhD in epidemiology and social medicine in 1994 from the University of Antwerp, Belgium.

In 2000, Professor Van Damme was appointed Professor at the Faculty of Medicine and Health Sciences, University of Antwerp - he teaches infectious diseases and vaccinology in the Faculty of Medicine and Health Sciences as well as in the Faculty of Pharmacy and Biomedical Sciences. He has authored more than 300 peer-reviewed papers and is on the editorial board of several scientific journals that focus on the study of vaccines and vaccine-preventable infectious diseases. Professor Van Damme was awarded with the Research Award of the University of Antwerp, and in 2000 with the Belgian Social Medicine Award ‘Jean Van Beneden’ for his work on the introduction of universal hepatitis B immunization programs. In May 2014, he was awarded with the prestigious Bill Marshall award of the ESPID society. 

Since 1994, he has served as the executive secretary of the Viral Hepatitis Prevention Board (VHPB), a group of international experts dealing with topics on prevention and control of viral hepatitis. His current research projects at the University are focused on the epidemiology and prevention of vaccine-preventable infectious diseases, such as hepatitis A, hepatitis B, diphtheria, pertussis, varicella, rotavirus, measles, HSV, influenza, and HPV. His research also concerns occupational health, youth health and preventive health for sex workers.

Professor Van Damme has been a regular advisor for national and international organizations for more than 10 years, including the Flemish Vaccination platform, the National Immunization Technical Advisory Group, and the World Health Organization (European Regional Office and Headquarters). He has been appointed as chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE).

Speakers
Prof. Markus Peck-Radosavljevic, Klinikum Klagenfurt
Speakers
Prof. Markus Peck-Radosavljevic, Klinikum Klagenfurt
_chair

Professor Markus Peck-Radosavljevic, MD MBA is Professor of Medicine and Chairman at the Department of Gastroenterology & Hepatology, Endocrinology and Nephrology at Klinikum Klagenfurt in Klagenfurt, Austria.

Professor Peck has served as Vice-secretary of the European Association of the Study of the Liver (EASL) from 2011 to 2013 and as Secretary General of EASL from April 2013 to April 2015. He also served as the Secretary General of the Austrian Association for Internal Medicine from 2006-2014.

He began his research in liver disease in the field of portal hypertension and he is running a translational lab testing novel approaches to the treatment of portal hypertension and HCC. Later, he has been actively involved in the management of post-OLT hepatitis C and started running trials in HCV-infection in hemodialysis patients and HIV-HCV coinfection.

Over the last few years, Professor Peck has been leading the Portal Hypertension, the HIV-HCV-Coinfection, and the Hepatocellular Carcinoma (HCC) Study Groups at the Medical University of Vienna, Austria, where he has been conducting a number of clinical trials in these indications as well as on new antivirals in HCV-infection in special indications. Since January 2016, he has taken over as Chair of Internal Medicine and Gastroenterology & Hepatology in Klagenfurt.   

Speakers
Prof. Massimo Colombo, University of Milan, Moderator
Speakers
Prof. Massimo Colombo, University of Milan, Moderator
_chair

Massimo G. Colombo is Professor of Gastroenterology at the University of Milan, Italy. His research studies interests include diagnosis and treatment of viral hepatitis and liver cancer. He is Chairman of Department of Liver, Kidney, Lung and Bone Marrow Units and Organ Transplant and of the Division of Gastroenterology and Hepatology at the Policlinic University Hospital, Milan.

Professor Colombo received a medical degree in Medicine at University of Milan where he completed a residency in Gastroenterology at Policlinic Maggiore Hospital. He completed his fellowship in Liver Disease at the Mount Sinai Hospital in New York.

Professor Colombo was the Editor-in-Chief of the Journal of Hepatology from 2005 to 2009. He is affiliated with several professional Associations and Societies, including the American Association for the Study of the Liver and the European Association for the Study of the Liver and other professional bodies in Italy. He is an international lecturer and speaker, sits on the editorial board of many Hepatology journals globally and has published more than 380 original manuscripts in peer-reviewed journals; 15,887 citations and H-index 52.

In 2010 he received the EASL Recognition Award by the European Association for the Study of the Liver for outstanding medical and scientific contribution. In 2014 he received the A.I.S.F. Distinguished Service Award by the Italian Association for the Study of the Liver (AISF). In 2014 he also received the Thannhauser Medal Award from the German Gastroenterology Society for clinical and scientific contributions in the field of liver disease.

Speakers
Prof. Nurdan Tözün, Acibadem University
Speakers
Prof. Nurdan Tözün, Acibadem University
_chair

Professor Nurdan Tözün earned her medical degree from Istanbul University Istanbul Faculty of Medicine and made her postgraduate training in Internal Medicine and Gastroenterology at the same Faculty.

She worked at Marmara University School of Medicine as head of GI department, Dean of medical school and Director of the first Institute of Gastroenterology of Turkey of which she has been the founder in 1992. She formerly served as president of the Turkish Association for the Study of the Liver and the Turkish Society of Gastroenterology.

Professor Tözün actively worked as a member of various international councils, executive committees or subcommittees including at the World Gastroenterology Organisation, at United European Gastroenterology (UEG – Public Affairs Committee), at the American Gastroenterological Association (AGA – Ethics Committee), and at the Asian Pacific Association for the Study of the Liver (APASL - Administrative Council). Currently she serves as the Chairperson of the Training Recognition Committee of the European Board of Gastroenterology and Hepatology. Her main areas of research and interest are viral hepatitis, colorectal cancer and Inflammatory Bowel Diseases.

Professor Tözün is the author of 95 articles in peer reviewed journals, 65 articles in Turkish, 4 book chapters in English and 12 in local languages she received several awards for her studies. She concentrated her efforts on the prevention and control of viral hepatitis as well as colorectal cancer in the Mediterranean Region. She is the current president of Mediterranean Task Force for Cancer Control (MTCC), an organization which aims to raise public awareness about cancer.

Since 2007 she has worked as the Head of Gastroenterology and Internal Medicine departments at Acıbadem University School of Medicine for which she acted as founding Dean and vice-president.

Speakers
Prof. Heiner Wedemeyer, Hannover Medical School
Speakers
Prof. Heiner Wedemeyer, Hannover Medical School
_chair

Professor Heiner Wedemeyer is the Managing Senior Physician and Associate Professor at the Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany. He coordinates the hepatitis diagnostic laboratory of Hannover Medical School (under the directorship of Prof. Michael P. Manns) and, together with Dr Markus Cornberg, he is leading a research group on cellular immunology in viral hepatitis.

Professor Wedemeyer received his degree in medicine from the University of Göttingen, Göttingen, Germany in 1996. He trained in Internal Medicine at Hannover Medical School, Germany. From 1998 to 2000, he was a research fellow in Immunology within the group of Dr Barbara Rehermann in the Liver Diseases Section, National Institutes of Health, Bethesda, MD, USA. In 2001, he returned to Hannover and completed his specialist training in Gastroenterology and Hepatology.

Professor Wedemeyer is involved in the scientific coordination of the German Network of Competence on Viral Hepatitis (Hep-Net) and the German Liver Foundation. In 2008, he was elected as a Scientific Committee member of the European Association for the Study of the Liver (EASL) and was Secretary General of EASL from 2009 to 2011. Professor Wedemeyer has worked on basic and clinical aspects of hepatitis virus infections throughout his career. His main interest is the immunopathogenesis of HBV, HCV, HDV and HEV infection and the development of novel immunomodulatory therapies, such as therapeutic vaccines in HCV. He has been principal investigator on clinical trials focusing on antiviral and immunotherapy use in viral hepatitis.

He has authored over 200 original articles, 100 reviews and editorials and 50 book chapters, and is the editor of four books. He has received numerous awards, including the Innovation Award of the German Medical Faculties (2011) and the Rudolph-Schoen-Award (2011).

Speakers
Prof. George Papatheodoridis, University of Athens
Speakers
Prof. George Papatheodoridis, University of Athens
_chair

George V. Papatheodoridis is Associate Professor in Medicine and Gastroenterology at the Medical School of Athens University and has been working at the 2nd Department of Internal Medicine in Hippokration General Hospital of Athens, Greece, since 1999. He was trained in Medicine and completed his MD thesis on “Acute on Chronic Hepatitis B” at the Medical School of Athens University. He was also trained in Gastroenterology at Tzaneion General Hospital of Piraeus, Greece and had a 2-year research fellowship in Hepatology at the Royal Free Hospital of London, UK.

Professor Papatheodoridis is a member of the Scientific Committee/Governing Board of the European Association of the Study of the Liver (EASL) and a member of the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA-fellow) and International Association for the Study of Liver (IASL). He is the general secretary of the Hellenic Society of Gastroenterology and has been the general secretary of the Hellenic Association for the Study of Liver and the chairman of its Research Committee. He is also vice secretary of the Hellenic Foundation of Gastroenterology & Nutrition and member of the Scientific Committee for Viral Hepatitis of the Hellenic Center for Prevention of Diseases.

Professor Papatheodoridis’ main research interest has been focused on viral hepatitis, but he has also worked in other research areas of Hepatology and Gastroenterology. He has authored or co-authored more than 160 papers published in international journals having more than 3500 citations (h-index 31). He has served as a reviewer for all gastroenterology and hepatology journals, for many major internal medicine journals (Lancet, Ann Intern Med, BMJ etc) as well as for EASL abstracts and the EU’s 7th Framework Programme for Research.

Speakers
Mr Charles Gore, World Hepatitis Alliance & Co Chair HepBC PPA
Speakers
Mr Charles Gore, World Hepatitis Alliance & Co Chair HepBC PPA
_chair

Charles Gore was diagnosed with hepatitis C in 1995 and cirrhosis in 1998 and in 2000 he set up The Hepatitis C Trust together with 3 friends who also had hepatitis C. He has worked extensively with Government Departments and the National Health Service (NHS) in the UK, championing the patient perspective. He worked with the Scottish Government and the Welsh Public Health Service in the development and implementation of their respective hepatitis C Action Plans and was on the Programme Board of the English National Liver Disease Strategy. In 2011 the Department of Health asked him to become one of the three founding trustees of the Caxton Foundation, the charity set up to administer discretionary payments to those infected with hepatitis C through the NHS.

He was closely involved in the creation of the European Liver Patients Association and was elected its first President from 2004 to 2006. In 2007 he established the World Hepatitis Alliance, of which he is President, and was the driving force behind the WHO’s adoption of World Hepatitis Day and the creation of WHO’s Global Hepatitis Programme. The World Hepatitis Alliance is WHO’s official partner in co-ordinating World Hepatitis Day each year.  Charles Gore continues to work closely with WHO globally and regionally and with individual Member States as they look to develop national hepatitis strategies. Mr Gore is part of the WHO Global Hepatitis Network and sits on the WHO Guidelines Development Groups for both hepatitis B and hepatitis C testing, care and treatment. He is also a member of the WHO Director-General’s Strategic and Technical Advisory Committee on Viral Hepatitis.

Speakers
Prof. Antonio Craxi – University of Palermo
Speakers
Prof. Antonio Craxi – University of Palermo
_chair

Dr. Antonio Craxi is a Full Professor of Gastroenterology at the University of Palermo, Italy where he also holds the post of Director of the Unit of Gastroenterology and Hepatology.

He received his medical degree from the University of Palermo where he graduated summa cum laude in 1975.  He completed a residency in Gastroenterology at the University of Rome, Italy.  Upon completion of his residency, Professor Craxi served as a N.A.T.O. research fellow in the Academic Department of Medicine at the Royal Free Hospital in London England.  He completed this fellowship in 1981 and at that time became a lecturer in the Academic Department of Medicine at the University of Palermo, Italy.  Professor Craxi joined the faculty of the University of Palermo as an Associate Professor in 1988 and as a full Professor of Internal Medicine and Gastroenterology in 1995.

Professor Craxi has published about 400 research articles in international journals.  He has given over 300 presentations to international and national meetings.  He is a member of numerous international societies including the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Disease (AASLD). He has chaired the Committee for the 2012 EASL Clinical Practice Cuidleine on HCV. He serves on the editorial board for various international journals (Hepatology, Journal of Hepatology, DLD, WJG).

His research interests include the epidemiology and natural course of liver diseases, antiviral treatments for HCV and HBV, hepatocellular carcinoma and metabolic liver diseases.

Speakers

Speakers
Prof Angelos Hatzakis, Co-Chair HepBC PPA and University of Athens
Speakers
Prof Angelos Hatzakis, Co-Chair HepBC PPA and University of Athens
_speaker

Angelos Hatzakis, MD, PhD, MSc, is Professor of Epidemiology & Preventive Medicine and Director of the Department of Hygiene, Epidemiology & Medical Statistics at Athens University Medical School. He is also Head of the National Retrovirus Reference Center. He trained in Internal Medicine (“Hippokratio” General Hospital of Athens) and Epidemiology (Harvard School of Public Health). He has served in many Executive Committees including the presidency of the Hellenic CDC. Professor Hatzakis is Co-Chair and founder of the Hepatitis B and C Public Policy Association. His research interests cover epidemiology, virology and prevention of viral diseases and oncogenic viruses. He is the author or co-author of more than 200 scientific papers published in journals like Lancet, JAMA, Plos Medicine, British Medical Journal, Annals of Internal Medicine, Proceedings of the National Academy of Science/PNAS, AIDS, Journal of AIDS, Journal of Infectious Diseases, Hepatology, Gastroenterology, Antiviral Therapy, Blood, Cancer Research, Pediatrics etc.

Speakers
Mr. Vytenis Andriukaitis, European Commissioner for Health
Speakers
Mr. Vytenis Andriukaitis, European Commissioner for Health
_speaker

Dr. Andriukaitis is the European Commissioner for Health and Food Safety, a position he has held since November 2014. One of the founders of the Lithuanian social-democratic party and a signatory of the Independence Act of Lithuania, Andriukaitis was previously a Member of the Lithuanian Parliament for six mandates. From 2001 to 2004 he was Deputy Speaker of the Lithuanian Parliament. From 2012 to 2014 Vytenis Andriukaitis was Minister for Health. In 2014 he also served as Vice-President of the World Health Assembly.

Commissioner Andriukaitis obtained a medical doctorate, specialising in surgery, from the Kaunas Medical Institute in 1975 and thereafter practised for nearly 20 years as surgeon. From 1989 to 1996 he was a member of the Lithuanian Doctors’ Association, and from 1998 to 2004 of the International Doctors’ Association. Dr. Andriukaitis also worked as Lecturer at the Lithuanian State Environmental Health Centre.

Speakers
Mr. Cristian Silviu Busoi, MEP
Speakers
Mr. Cristian Silviu Busoi, MEP
_speaker

Cristian-Silviu Bușoi is a Romanian physician and politician. He is a Member of the European Parliament (MEP) and Co-chair of the MEP Friends of the Liver Group.

Dr. Bușoi graduated in 2003 from the Medicine Faculty of the Carol Davila University of Medicine and Pharmacy in Bucharest. In 2004, he also began work on two doctorates: one in Endocrinology at his alma mater, and one in Public Health and Health Management at the Victor Babeş University of Medicine and Pharmacy in Timişoara. Since 2007, he has been a lecturer at the latter institution, in the same field. In 2005, he received a degree from the Carol I National Defence University, and in 2007 he completed studies at the Law Faculty of Titu Maiorescu University.

Dr. Bușoi's political career began in 1996, when he joined the National Liberal Party (PNL). His first elected office was as a member of the General Council of Bucharest, where he sat from May to December 2004. At the 2004 legislative election, he won a seat in the Chamber of Deputies, where he sat on the health and family committee and formed part of the Romanian Parliament's delegation to the Assembly of the Western European Union. In April 2007, following the resignation of Adrian Cioroianu to become Foreign Affairs Minister, Bușoi was named an MEP. Following a by-election that November, he was elected an MEP and resigned his Chamber seat. He was re-elected at the June 2009 European Parliament election. In the European Parliament, he sat on the Committee on Internal Market and Consumer Protection. In June 2013, he was named head of Romania's National Health Insurance Fund, subsequently resigning from the European Parliament. He resigned from this office in early 2014, when the PNL left the governing coalition. At that year's May European Parliament election, he won a new term as an MEP. Dr. Bușoi is currently among others a member of the European Parliament’s Committee on the Environment, Public Health and Food Safety and one of the leading MEPs on public health issues.

Speakers
Dr Tatjana Reic, ELPA
Speakers
Dr Tatjana Reic, ELPA
_speaker

In 2000 Dr. Reic founded “Hepatos”, the first liver patients’ association in Croatia. Thanks to her well-argued and determined declarations, “Hepatos” has become a leading civil society organisation in Croatia whose contribution towards the recognition of viral hepatitis as a social problem in the past decade has been crucial.

Dr. Reic is also a member of the Croatian National Committee for Viral Hepatitis and a founding member of the Croatian Alliance of Hepatitis Patients. Since April 2011, she has served as the President of the European Liver Patients’ Association (ELPA). ELPA is dedicated to promoting the interests of people with liver diseases at European level, by raising awareness on the issue of prevention among healthcare professionals, policy-makers and the wider public, especially in the field of viral hepatitis. At international level, Dr. Reic is involved as an advisor on various committees, working groups and/or associations such as Viral Hepatitis Prevention Board (VHPB).

Tatjana Reic is a doctor of veterinary medicine by profession, having graduated in 1983 and done her Master of Science degree from the Faculty of Veterinary Medicine in Zagreb in 1997.

Speakers
Mr. Eberhard Schatz, Correlation Network
Speakers
Mr. Eberhard Schatz, Correlation Network
_speaker

Since 2005, Eberhard Schatz is one of the coordinators of Correlation – European  Network Social Inclusion and Health, with more than 180 partners from all over Europe. He is responsible for the overall management of the project, the organisation of seminars and conferences and numerous publications and reports. Correlation is member of the Civil Society Forum on Drugs, which he chaired a couple of years. In addition, he is coordinator of the Correlation Hepatitis C Initiative. He is involved in different external projects, advisory boards at the national and international level.

Prior to serving as one of coordinators of the Correlation Network Eberhard Schatz studied social work in Germany and worked for drug counselling services in Germany and cross-border projects between Germany and the Netherlands. From 1998 to 2004, he coordinated the European project AC Company, a network, targeting mobile drug users in Europe. 

Speakers
Prof. Helena Cortez-Pinto, EASL
Speakers
Prof. Helena Cortez-Pinto, EASL
_speaker

Professor Helena Cortez-Pinto is presently EU Policy Councillor-Elect of the European Association for the Study of the Liver (EASL). From June 2013 to June 2015 she served as the President of the Portuguese Association for the Study of the Liver. Between 2009 and 2013 she was EASL’s representative at the Scientific Committee of the United Gastroenterological Federation (UEG). She is Associate Editor of Liver International (2006-present), and member of the Editorial Board of Journal of Hepatology (2006–present), and Hepatology (2008-2011). She co-organized two monothematic EASL meetings on Nonalcoholic Steatohepatitis in 2004 and 2009.

Professor Helena Cortez-Pinto is recipient of the prize: “Rising Star in Gastroenterology - UEG”. Major research interests include alcoholic and non-alcoholic fatty liver disease. She has recently developed and implemented a project for National Registry of Liver Patients, named Liver.pt, aiming to put together clinical, laboratory and histological data from ambulatory liver patients, while simultaneously being a clinical process with algorithms and scores embedded. She has published original papers in a number of scientific journals, including JAMA, Gastroenterology, Hepatology, Journal of Hepatology and Liver International.

Since 2008, she is Associate Professor of Medicine in the Faculty of Medicine of Lisbon. She is the President of the Commission of Pharmacy and Therapeutics, and Coordinator of a section of the Gastroenterology Department, in the University Hospital of Santa Maria.

Helena Cortez-Pinto graduated from the Faculty of Medical Sciences of Lisbon, in 1981. Between 1985 and 1990, she did her internship in Gastroenterology in the University Hospital of Santa Maria. In 1998, Professor Cortez-Pinto did a research fellowship during 6 months at Johns Hopkins University, investigating in the area of non-alcoholic fatty liver disease. In 2000, she presented her PhD entitled “Steatosis and non-alcoholic steatohepatitis. Clinical aspects and pathogenic mechanisms”.  

Speakers
Dr. Homie Razavi, Center for Disease Analysis
Speakers
Dr. Homie Razavi, Center for Disease Analysis
_speaker

Dr. Homie Razavi is the founder and managing director at the Center for Disease Analysis (CDA) in Louisville CO, USA, an organization specializing in studying complex and poorly understood diseases.

CDA’s goal is to study and publish data to help educate stakeholders and support decision-making in different countries. Since 2008, Homie has led a team of epidemiologists and modellers to quantify epidemiology of hepatitis C virus and forecast the future impact of HCV disease burden.  They have analysed HCV disease burden in over seventy countries and have helped countries develop national strategies.

His team has been responsible for the development of a number of mathematical models currently used by countries around the world to develop intervention strategies for HCV and HBV: HCV disease progression; HCV transmission; HCV cost effectiveness; HBV vertical transmission; HBV disease progression/treatment. In addition, his team is currently developing the Polaris Observatory, which will collect and report HCV, HBV and HDV epidemiology, disease burden and treatment rate annually for all countries. He has a broad background, which includes basic research, commercial development, portfolio management, and decision analysis. He is also a fellow in the Decision Professional Society.  

Speakers
Dr. Stephan Wiktor, World Health Organisation
Speakers
Dr. Stephan Wiktor, World Health Organisation
_speaker

Dr. Stefan Wiktor is a public-health physician with more than twenty-five years’ experience in epidemiologic research and implementation of public-health programs. Dr. Wiktor is currently the Team Lead of the World Health Organization’s Global Hepatitis Programme in Geneva, Switzerland which works with WHO Regional and country officials to promote the implementation of comprehensive viral hepatitis prevention and control programs. While working for the U.S. Centers for Disease Control and Prevention, he conducted research studies of HIV-1 and HIV-2 epidemiology in West Africa and led the implementation of a large-scale HIV/AIDS prevention and treatment program in Tanzania.

Dr. Wiktor is the author of more than 100 peer-reviewed scientific publications. He received his medical degree from Pennsylvania State University School of Medicine, public health degree from Johns Hopkins University and completed his internal medicine training at Georgetown University.

Speakers
Prof. Jagpreet Chhatwal, Massachusetts General Hospital
Speakers
Prof. Jagpreet Chhatwal, Massachusetts General Hospital
_speaker

Jagpreet Chhatwal is an assistant professor of Radiology at Harvard Medical School and a senior scientist at the Massachusetts General Hospital. Professor Chhatwal’s research interests include health economics and outcomes research. Using operations research methods, his work aims to inform health policies and improve clinical decision-making. His recent research on hepatitis C modelling and cost-effectiveness has made a direct impact on defining hepatitis C screening and treatment policies. His work on the cost and impact new hepatitis C treatment was featured by The Wall Street Journal, Forbes, The Washington Post and CNBC.

In addition, his research interests include advancement of decision-analytic methods used for medical decision-making. Professor Chhatwal regularly teaches methods-oriented workshops at the annual meetings of the Society for Medical Decision Making and International Society for Pharmacoeconomics and Outcomes Research. He is also an editorial board member of Medical Decision Making.

Previously, Professor Chhatwal worked as a health economist for Merck Research Laboratories and was a faculty member at the University of Pittsburgh Graduate School of Public Health and MD Anderson Cancer Center. 

Speakers
Mr. Achim Kautz, ELPA
Speakers
Mr. Achim Kautz, ELPA
_speaker

Achim Kautz was among the founding Members of the European Liver Patients Association (ELPA) in 2004 and in 2014 was one of the founders of the Leberhilfe Projekt gUG. He has been a Member of the Board of the German Network of Excellence for Viral Hepatitis (Hep-Net) between 2002 and 2006, Chairman of the Board of BAG Leber e. V. since 2003, and Member of the Board of Trustees of the Deutsche Leberstiftung since 2006. In 2008 he became a special consultant for the World Hepatitis Alliance and in 2010 he was among the founding members of the German workgroup “National Liver Strategy Plan”.

Speakers
Mr. John F. Ryan, European Commission
Speakers
Mr. John F. Ryan, European Commission
_speaker

John F. Ryan is Acting Director of the Public Health directorate in the European Commission Directorate General for Health and Food Safety (DG SANTE). He is also the current Head of Unit responsible for health threats (communicable diseases, health security and bioterrorism) within DG SANTE. This includes responsibility for issues such as surveillance of communicable diseases, strategies for prevention and EU and international cooperation on health security.

Within the European Commission John F. Ryan was previously responsible for the health information programme, the cancer programme, the pollution related disease programme, the drugs prevention programme, the health monitoring programme, the health promotion programme, the rare diseases programme and the injury prevention programme. John F. Ryan was previously a European Commission representative on the Board of the EU Lisbon Drugs Agency, and is currently the European Commission representative on the Board of the European Centre for Disease Prevention and Control (ECDC).

Speakers
Dr. Ingo Michels, Federal Ministry of Health, Germany
Speakers
Dr. Ingo Michels, Federal Ministry of Health, Germany
_speaker

Since 1999, Dr. Ingo Ilja Michels is the Head of the Office of the Federal Drug Commissioner. He is responsible for the coordination of creating and implementing the national “Action Plan on Drugs and Addiction” for the representation of the Federal Drug Commissioner and the Federal Drug Policy on national and international level. From February 2010 to June 2013, he worked as a project leader of the EU Central Asia Drug Action Programme (CADAP) Project with Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ).

Speakers
Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris
Speakers
Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris
_speaker

Yazdan Yazdanpanah, Professor of Infectious Disease, Bichat Claude Bernard Hospital and Paris Diderot University, France

Yazdan Yazdanpanah is currently the Head of Infectious Disease department at Bichat Claude Bernard Hospital and Professor of Medicine at Paris Diderot University, France. Yazdan Yazdanpanah became an MD from the Lille School of Medicine, France in 1996. He qualified from the same institution first as a hepato- gastro-enterologist in 1996 and next an infectious disease specialist in 2002. He obtained a Master of Science degree in epidemiology from the Harvard School of Public Health, Boston, US in 2000, and a Ph.D degree in public health from the Bordeaux School of Public Health in 2002. In 2006, he became Professor of Infectious Disease.  His research interests include the clinical epidemiology of HIV and viral hepatitis, and the pharmaco-economics of antimicrobial agents. Professor Yazdanpanah has published extensively in peer-reviewed journals and makes frequent presentations at numerous national and international meetings.

Speakers
Prof. David Goldberg, Health Protection Scotland
Speakers
Prof. David Goldberg, Health Protection Scotland
_speaker

Professor Goldberg is a Consultant Clinical Epidemiologist at Health Protection Scotland. He is also Professor of Public Health at Glasgow Caledonian University and an Honorary Professor of Public Health at the University of Glasgow.

Professor Goldberg led the team which secured a £100 million investment for Scotland’s Hepatitis C Action Plan to improve prevention, diagnosis and treatment services during 2008-2015. He, as Chair of Scotland’s Hepatitis C Action Plan Governance Board, led the co-ordination of the Plan during the period above and now chairs the Scottish Government’s Hepatitis C Treatment and Therapies Group for Scotland’s Sexual Health and Blood Borne Virus Framework. He Chairs the UK Advisory Panel for Healthcare Workers with Blood Borne Viruses and Chairs the Scottish Government’s Penrose Inquiry Recommendation Implementation Group.

Speakers
Dr. Luís Mendão, Chairman, GAT, Portugal
Speakers
Dr. Luís Mendão, Chairman, GAT, Portugal
_speaker

Dr. Luís Mendão is currently Chair of the Board of GAT –Treatment Activist Group, an NGO founded in 2001 and working in prevention, early diagnosis, treatment and care of HIV/AIDS, viral hepatitis and tuberculosis focus on key populations. He is also the founder and on the Board of Directors of the Anti Prohibitionist Association (SOMA-APA). Represents Portugal in the Civil Society Forum on HIV/AIDS at the European Commission and he’s a member and Chair of the European AIDS Treatment Group (EATG). Luís Mendão is part of the Steering Committee of the HIVPORTUGAL initiative. In the last ten years, it has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC. Luís Mendão was diagnosed with HIV and HCV in 1996. Dr. Mendão concluded his studies in biochemistry in 1983 at the University Pierre et Marie Curie, in Paris.

Speakers
Dr. Freke Zuure, Department of Infectious Diseases Research & Prevention, The Netherlands
Speakers
Dr. Freke Zuure, Department of Infectious Diseases Research & Prevention, The Netherlands
_speaker

Dr. Freke Zuure studied health communication science and currently works as a post doc researcher at the infectious diseases department of the Public Health Service of Amsterdam, The Netherlands. She completed her PhD in 2013 on hepatitis C virus screening within the general population. In the past ten years she has led various screening projects for hepatitis B, C and HIV. She coordinates the Amsterdam initiative for a joint action plan for hepatitis B and C prevention and care. Her research interests include the epidemiology and identification of hepatitis B, C and HIV infections, innovative screening options, self-testing and eHealth.

Speakers
Dr. Ricardo Baptista Leite, Catholic University, Portugal
Speakers
Dr. Ricardo Baptista Leite, Catholic University, Portugal
_speaker

Ricardo Baptista Leite is a Medical Doctor trained in infectious diseases and is currently Head of Public Health and lead for strategic planning and development at the Institute of Health Sciences of the Catholic University of Portugal.

He is also Guest Lecturer at NOVA Medical School (NOVA University, Lisbon), where he has been teaching microbiology for the past 8 years. Dr. Baptista Leite was appointed as Senior Fellow at New Westminster College (BC, Canada) in 2013 and is currently a PhD candidate in Public Health at Maastricht University (The Netherlands). Last year he was elected member of the supervisory board of the National Genetic Database Protection Agency. Dr. Baptista Leite is also a medical consultant at Glintt Healthcare Solutions, a multinational company in the field of information technologies geared towards healthcare.

Alongside his academic achievements, Dr. Baptista Leite is active in politics. He is currently City Councillor of Cascais where he is responsible for local health policy, academic partnerships and international relations (including economic diplomacy). Ricardo Baptista Leite is also a former Member of the Portuguese Parliament (2 terms | 2011-2015) where he was among others a permanent member of the Parliamentary Health Committee and Chair of the all-party Parliamentary HIV/AIDS workgroup.

Prior to being elected as member of the Portuguese Parliament, Dr. Baptista Leite worked for 7 years as a practicing physician, having completed 5 years of an Infectious Diseases residency program at the Western Lisbon Hospital Center. During this residency program, he completed in 2011 an internship in public health (HIV, Hepatitis and STI’s) as a formal collaborator of the World Health Organization Regional Office for Europe, based in Copenhagen.

Dr. Baptista Leite is the sole founder of CREATING HEALTH – Research and Innovation funding, a sustainable non-profit which has been set up within the Catholic University of Portugal to help capture funding for health innovation and research projects (http://creatinghealth.ics.lisboa.ucp.pt). 

Dr. Baptista Leite was the main author of the “Strategic Consensus on Integrated Management of Hepatitis C in Portugal”, published as a book in May 2014. This consensus was a breakthrough study in the field of public health and summarized the main conclusions of a think tank which included Portugal’s 30 main experts in the field, following over 6-months of meetings and discussions. He is also the main author of the book “Citizenship for Health” (2015) which is focused on the role of Citizens in health promotion and disease prevention.

Speakers
Dr. Antons Mozalevskis, WHO Europe
Speakers
Dr. Antons Mozalevskis, WHO Europe
_speaker

Dr. Antons Mozalevskis is currently working as a Medical Officer at the WHO Regional Office for Europe in Copenhagen, Denmark. He is responsible for all viral hepatitis-related activities at the Regional Office and technical support to the Member States in the Region. He completed his medical training and residency in Family Medicine at Riga Stradins University, Latvia. He worked as a clinician for seven years and was involved in a number of civil society, professional organisations and regional expert networks active in the field of HIV/viral hepatitis prevention and research. In 2012–2014, he completed the European Programme for Intervention Epidemiology Training (EPIET) and received a Master Degree in Applied Epidemiology from the National School of Public Health in Madrid, Spain.

Speakers
Dr. Erika Duffell, ECDC
Speakers
Dr. Erika Duffell, ECDC
_speaker

Dr. Erika Duffell is a public health doctor who specialises in the field of communicable disease control. She previously worked for 7 years as a consultant in health protection with the Health Protection Agency in the northwest of England. Since 2011, she has worked at the European Centre for Disease Prevention and Control (ECDC) in Stockholm in the area of hepatitis B and C. Her work at ECDC has involved the implementation of an enhanced surveillance programme across EU/EEA countries, the running of the European Hepatitis B and C Network and the development of a programme of activities relating to the surveillance, prevention and control of hepatitis B and C.

Speakers
Mr. Alexis Goosdeel, EMCDDA
Speakers
Mr. Alexis Goosdeel, EMCDDA
_speaker

Alexis Goosdeel took up the post of Director of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on 1 January 2016, having been formally appointed to the position by the agency’s Management Board in October 2015 for a five-year term.

A Belgian national, Mr Goosdeel joined the EMCDDA in 1999 as a project manager working in the area of EU enlargement and international relations. From 2005, he headed the agency’s Reitox and international cooperation unit. In this capacity, he played a central role in coordinating a network of 30 national drug monitoring centres; preparing EU candidate and potential candidate countries for membership of the EMCDDA; developing cooperation with neighbouring countries to the EU; and nurturing relations with countries beyond the Union (Central Asia, Russia, Latin America). Mr Goosdeel has spent much of his 30-year career working in the field of public health at national, European and international level. He was one of the founders of Modus Vivendi, a Belgian NGO working in the area of harm reduction. Before joining the agency, he directed Alizés, a Brussels-based, European association working for development and cooperation in public health (1992-99). Mr Goosdeel holds a Master degree in clinical psychology and a special diploma in advanced management. 

Speakers
Dr. Ioannis Baskozos, General Secretary Public Health, Greece
Speakers
Dr. Ioannis Baskozos, General Secretary Public Health, Greece
_speaker

Dr. Baskozos is the first Vice President of the “Panhellenic Medical Association” and Secretary General for Public Health of the Greek Ministry of Health. He is Coordinator of the Committee for Refugees, Migrants and Vulnerable Groups. He is also Head of the Committee for the National Action Plan on Migration and Health and responsible for the development of the cooperation of the Ministry of Health with the World Health Organisation and other international organisations.

Previously Dr. Baskozos served as Vice President and Chairman of the Hellenic Endocrine Society, the scientific and professional syndicate of Greek Endocrinologists.

Dr. Baskozos completed his studies at the “Varvakios” model high school. He studied medicine at the National and Kapodistrian University of Athens, where he became a Medical Doctor and specialised in Endocrinology at the General Hospital “G. Gennimatas”. He has participated in congresses in Greece and abroad as a speaker and is the author of papers published in scientific magazines and congresses about endocrinology, diabetes and metabolism. 

Speakers
Prof. Jeffrey Lazarus, Centre for Health and Infectious Disease Research Copenhagen
Speakers
Prof. Jeffrey Lazarus, Centre for Health and Infectious Disease Research Copenhagen
_speaker

Professor Jeffrey V. Lazarus is a senior researcher based at CHIP, the Centre for Health and Infectious Disease Research and WHO Collaborating Centre on HIV and Viral Hepatitis at the University of Copenhagen. He is also a professor at the Lithuanian University of Health Sciences, Medical Academy, and an affiliated professor at the Institute of Public Health, University of Porto. His career as a health systems and communicable diseases expert at WHO’s Regional Office for Europe was followed by a stint at the Global Fund to Fight AIDS, Tuberculosis and Malaria, where he led knowledge translation.

Upon his return to Copenhagen in 2012, he became the co-founding secretariat director of Health Systems Global and a steering committee member of the Correlation Network HCV Initiative. He now serves as the Board Chair of AFEW, a steering committee member of the European Commission’s new Joint Action on HIV and Hepatitis (#HAREACT), and as Editor-in-Chief of Hepatology, Medicine and Policy.

Speakers
Prof. Mark Thursz, Imperial College, London
Speakers
Prof. Mark Thursz, Imperial College, London
_speaker

Mark Thursz is professor of hepatology at Imperial College where he is head of the Digestive Diseases Division and also lead clinician for hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease. He is a vociferous advocate for programme development to treat hepatitis B and hepatitis C infections in resource constrained settings and in marginalised populations. He is chief investigator on the PROLIFICA programme (www.prolifica.eu) in West Africa.

Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants. Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.

Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and has recently completed his term as Secretary-General of the European Association for Study of the Liver (EASL). He remains active in advocacy for treatment availability for patients with viral hepatitis and for government policy to reduce alcohol consumption. He is chair of the Hepatitis C Coalition, a group of professional and patient representative groups working together towards the elimination of HCV in the UK.

Speakers
Prof Michael P. Manns, Co-Chair HepBC PPA and Hannover Medical School
Speakers
Prof Michael P. Manns, Co-Chair HepBC PPA and Hannover Medical School
_speaker

Michael P. Manns is Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), Hannover, Germany since 1991. He graduated in medicine from the University of Vienna in Austria and the University of Mainz in Germany before completing postgraduate training at the Free University of Berlin, Germany, and the University of Mainz, where he became Professor of Medicine in 1986. Subsequently, Professor Manns was a Research Associate at the Scripps Research Institute in La Jolla, California, USA from 1987 to 1988. Professor Manns has a long-term research interest in liver diseases with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular carcinoma, liver transplantation, regenerative medicine, and cell therapy.

Professor Manns is founder and Chairman of Hep-Net, a national network of competence on viral hepatitis, and the German Liver Foundation. He has been President of the German Society of Gastroenterology (DGVS), the German Association for the Study of the Liver (GASL) and the German Society of Internal Medicine (DGIM), and is currently President Elect of United European Gastroenterology (UEG). Professor Manns has received numerous awards including the International Hans Popper Award and the European Association for the Study of the Liver (EASL) Recognition Award in 2007. He organized numerous national and international conferences including the Global Viral Hepatitis Summit on occasion of the 15th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) in Berlin, Germany, in June 2015. Since 2015 he is member of the Scientific Panel for Health (SPH) of the European Commission in Brussels. He has published more than 1000 articles in international peer-reviewed journals such as the New England Journal of Medicine, The Lancet, Nature, Nature Medicine, Cell, Gastroenterology, and Hepatology among others. He has an H-Index of 119. According to Thomson Reuters he ranks among the top 1 % of most cited researchers in clinical medicine.

Speakers
Mr George A. Papandreou, President of the Socialist International and former Prime Minister of Greece
Speakers
Mr George A. Papandreou, President of the Socialist International and former Prime Minister of Greece
_speaker

George A. Papandreou is former Prime Minister of Greece (2009-2011). 

Currently he is the President of the Socialist International (since 2006- ) the largest global organization of progressive political parties. 
He is also President of the newly founded party Movement of Democratic Socialists. 
He is the Vice President of the Foundation for Olympic Truce. 
He is a member of the Global Leadership Council of Sustainable Development Solutions Network - A Global Initiative for the United Nations.
He is a member of the Global Leadership Council of the humanitarian organization Mercy Corps.
He is a Commissioner of the Global Commission on Drug Policy. 
He is a member of Club de Madrid. 
He was Leader of the Panhellenic Socialist Movement from 2004 until 2012. 
As Foreign Minister from 1999–2004, he was widely praised for his diplomatic bridge building. He successfully negotiated better relations with former rival Turkey.
As Education Minister from 1994-1996, George Papandreou founded Open University in Greece, an innovative national effort to facilitate undergraduate and graduate distance learning. 
He was named as one of Foreign Policy magazine’s Top 100 Global Thinkers in 2010 for “making the best of Greece’s worst year.”
He completed his university studies at Amherst College in Massachusetts and graduate studies at the London School of Economics.

With financial support of

Official endorsements